Subsense Inc develops non-invasive, nanoparticle-based brain–computer interface technologies designed to enable bidirectional neural interfacing without surgical implantation. The company’s platform focuses on precise neural recording and stimulation using targeted nanoparticles that interact with brain tissue. Its approach aims to provide the capabilities of invasive BCIs while avoiding surgical risks. Subsense Inc positions its technology within experimental neurotechnology and future therapeutic development contexts.

The technology leverages engineered nanoparticles that respond to external stimuli, allowing localized stimulation and detection of neural activity. These particles can be guided and activated non-invasively, enabling interaction with specific brain circuits. AI-driven signal processing decodes neural responses and adapts stimulation parameters in real time. The system emphasizes precision, safety, and repeatable operation without penetrating neural tissue.

Subsense Inc targets applications in advanced brain–computer interfacing, neuromodulation, and potential therapeutic use for neurological disorders. The platform is intended for research and early-stage clinical exploration rather than current clinical or consumer deployment. Its positioning reflects broader interest in non-surgical BCIs that combine minimally invasive delivery with high-resolution neural control.